The revenue decline reflects the conclusion of a major collaboration, but reduced R&D spending and strong cash position support continued clinical development. Investors should monitor upcoming data readouts from vopimetostat combination trials in 2026 as key value inflection points.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 5 $16.83entry
- T+1 · 9mo ago +0.71%α +2.03% · $16.95
- T+5 · 8mo ago +1.90%α +4.14% · $17.15
- T+20 · 8mo ago +28.52%α +32.31% · $21.63
- T+60 · 6mo ago +37.25%α +25.95% · $23.10
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Tango Therapeutics reported financial results for Q4 and full year 2025, showing a decline in revenue due to the conclusion of its Gilead collaboration, while R&D expenses decreased year-over-year. The company highlighted clinical progress with vopimetostat, including combination trials and a new supply agreement with Erasca, and announced leadership changes. Cash position of $343.1 million provides runway into 2028.
Key Financial Metrics
Key Facts
- Revenue dropped to $0 in Q4 2025 from $5.4M in Q4 2024, and full-year revenue decreased to $62.4M from $42.1M in 2024 due to completion of Gilead collaboration
- Net loss narrowed to $38.7M in Q4 2025 from $30.8M in Q4 2024, and full-year net loss decreased to $101.6M from $130.3M in 2024
- Cash, cash equivalents, and marketable securities totaled $343.1 million as of December 31, 2025, providing runway into 2028
- Company initiated a pivotal study for vopimetostat in 2L pancreatic cancer and entered a clinical supply agreement with Erasca for combination therapy
- Leadership changes included CEO succession from Dr. Barbara Weber to Dr. Malte Peters and appointment of Philippe Serrano as Chief Regulatory Officer
Financial Impact
Revenue decreased by $62.4M year-over-year due to completion of Gilead collaboration, while operating expenses decreased by $13.9M, resulting in improved cash preservation
Risk Factors
- Dependence on successful clinical development of vopimetostat, which remains investigational
- No current revenue from product sales with uncertain path to profitability
- High burn rate in a capital-intensive biotech sector requiring potential future funding
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-092535 |
| Document: tngx-20260305.htm | 0001193125-26-092535 |
| Document: 0001193125-26-092535-index-headers.html | 0001193125-26-092535 |
| Document: 0001193125-26-092535-index.html | 0001193125-26-092535 |
| Document: 0001193125-26-092535.txt | 0001193125-26-092535 |
Track record
27 reports on TNGX
3 of 7 bullish or bearish reports moved the stock their way by T+60. Best: +29.28% at T+60 after the Jun 8, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.22 Now $24.17 +0.21% settles Feb 16
- Nov 16, 2026today SC 13G/A Bearish 4/10 Entry $24.50 Now $24.17 +1.35% settles Feb 12
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $22.74 Now $24.17 +6.29% settles Feb 5
- Nov 6, 202610d ago SC 13G/A Neutral 2/10 Entry $21.50 Now $24.17 +12.42% settles Feb 4
- Nov 4, 202612d ago Insider Cluster Neutral 2/10 Entry $20.87 Now $24.17 +15.81% settles Feb 3
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Nov 2, 202614d ago 144 Neutral 2/10 Entry $23.17 Now $24.17 +4.32% settles Feb 1
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $23.34 Now $24.17 +3.56% settles Jan 21
- Aug 11, 202613w ago 8-K Bearish 6/10 Entry $25.58 to $23.18 Now $24.17 +5.51% ▲ +9.38% +4.51% vs SPY
- Aug 11, 202613w ago 8-K Bullish 7/10 No price data
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers